Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma
- PMID: 17522066
- PMCID: PMC2085367
- DOI: 10.1093/carcin/bgm121
Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma
Abstract
Background: Several previous studies have found non-Hodgkin lymphoma (NHL) risk to be associated with hair dye use, particularly use of permanent, dark colors and use before 1980, when hair dye formulations changed.
Methods: We examined NHL risk in relation to reported hair dye use among 1,321 cases and 1,057 controls from a US population-based multi-center study. DNA was extracted from blood or buccal cells to identify genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), which encode enzymes that metabolize aromatic amine compounds found in hair dyes.
Results: Among women, 509 cases and 413 controls reported hair dye use [odds ratio (OR) = 1.2; 95% confidence interval (95% CI) = 0.9, 1.6]. Risk estimates were higher for use before 1980 than for use in 1980 or later, particularly for use of permanent, intense tone (black, dark brown, dark blonde) products (<1980-OR = 1.6; 95% CI 0.9, 2.7; >or=1980-OR = 0.6; 95% CI 0.4, 1.1). Risk estimates were increased for women who used permanent, intense tone products before 1980 if they had the rapid/intermediate NAT2 phenotype (OR = 3.3; 95% CI 1.3, 8.6) or the NAT1 10 allele (OR = 2.5; 95% CI 0.9, 7.6), but not if they were slow NAT2 acetylators (OR = 1.5; 95% CI 0.6, 3.6) or had no copies of the NAT1 10 allele (OR = 1.5; 95% CI 0.7, 3.3). NHL risk was not increased among women who began hair dye use after 1980 or among men.
Conclusion: Our results support previous research demonstrating elevated NHL risk among women who used dark color or intense tone permanent hair dyes before 1980. We present the first evidence suggesting that this risk may differ by genetic variation in NAT1 and NAT2.
Conflict of interest statement
Comment in
-
Re: Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma, author response.Carcinogenesis. 2008 May;29(5):1084-5. doi: 10.1093/carcin/bgn023. Epub 2008 Jan 22. Carcinogenesis. 2008. PMID: 18212328 Free PMC article. No abstract available.
-
Reply: letter to the editor in response to Morton et al. (2007) Carcinogenesis, 28, 1759-1764.Carcinogenesis. 2008 Sep;29(9):1851. doi: 10.1093/carcin/bgn022. Epub 2008 Jan 24. Carcinogenesis. 2008. PMID: 18218828 No abstract available.
Similar articles
-
Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma.Pharmacogenet Genomics. 2006 Aug;16(8):537-45. doi: 10.1097/01.fpc.0000215071.59836.29. Pharmacogenet Genomics. 2006. PMID: 16847422 Free PMC article.
-
Re: Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma, author response.Carcinogenesis. 2008 May;29(5):1084-5. doi: 10.1093/carcin/bgn023. Epub 2008 Jan 22. Carcinogenesis. 2008. PMID: 18212328 Free PMC article. No abstract available.
-
Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium.Cancer Causes Control. 2013 Jan;24(1):125-34. doi: 10.1007/s10552-012-0098-4. Epub 2012 Nov 18. Cancer Causes Control. 2013. PMID: 23160945 Free PMC article.
-
Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):29-42. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 10667461 Review.
-
A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.Med Oncol. 2011 Mar;28(1):365-76. doi: 10.1007/s12032-010-9423-5. Epub 2010 Jan 23. Med Oncol. 2011. PMID: 20099048 Review.
Cited by
-
Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct.Carcinogenesis. 2012 Feb;33(2):348-55. doi: 10.1093/carcin/bgr273. Epub 2011 Nov 22. Carcinogenesis. 2012. PMID: 22114069 Free PMC article.
-
Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1.Drug Metab Rev. 2008;40(1):169-84. doi: 10.1080/03602530701852917. Drug Metab Rev. 2008. PMID: 18259988 Free PMC article. Review.
-
Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study.Int J Cancer. 2011 Aug 15;129(4):938-47. doi: 10.1002/ijc.25717. Epub 2010 Nov 23. Int J Cancer. 2011. PMID: 20949561 Free PMC article.
-
Risk of Carcinogenicity Associated with Synthetic Hair Dyeing Formulations: A Biochemical View on Action Mechanisms, Genetic Variation and Prevention.Indian J Clin Biochem. 2022 Oct;37(4):399-409. doi: 10.1007/s12291-022-01051-x. Epub 2022 May 17. Indian J Clin Biochem. 2022. PMID: 36262790 Free PMC article. Review.
-
Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma.Am J Epidemiol. 2008 Jun 1;167(11):1321-31. doi: 10.1093/aje/kwn058. Epub 2008 Apr 11. Am J Epidemiol. 2008. PMID: 18408225 Free PMC article.
References
-
- Thun MJ, Altekruse S, Namboodiri M, Calle EE, Myers D, Heath CW., Jr Hair dye use and risk of fatal cancers in U.S women. J Natl Cancer Inst. 1994;86(3):210–215. - PubMed
-
- Altekruse S, Henley SJ, Thun MJ. Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United States) Cancer Causes Control. 1999;10(6):617–625. - PubMed
-
- Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Flynn S, et al. Hair-coloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol. 2004;159(2):148–154. - PubMed